Medtronic plc (MDT) fair value analysis
S&P 500 · Updated 2026-10-19
MDT price how computed
Forward Fair Value verdict
UndervaluedMDT is trading at a 10–25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $88.48
- Sector
- Healthcare
- 12-month range
- $73.75–$105.35
- Market cap
- $113B
- From 52-week high
- -16.0%
- Shares outstanding
- 1.28B
- Rank in Healthcare by discount to fair value
- #41 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Medtronic plc is a medical technology company that develops, manufactures, and sells devices and therapies used in cardiac surgery, neurosurgery, spinal surgery, diabetes management, and other areas of medicine. The company operates globally with a significant presence in North America, Europe, and Asia-Pacific regions.
MDT currently ranks #41 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 6 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $113B
- P/E (trailing)
- 15x
- Revenue (TTM)
- $37.5B
- Net margin
- 13.9%
- EPS (TTM)
- $5.72
- Gross margin
- 65.0%
- Debt / equity
- 0.56
- Revenue growth (3-yr avg)
- 7.4%
- Shares outstanding
- 1.28B
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Expanding
- 52-week position
- The lower-middle quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 59 · neutral
- 50-day average
- $90.89
- 200-day average
- $88.30
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Dividends how computed
- Paid, last 12 months
- $2.86 per share (4 payments)
- Yield on last price
- 3.23%
- Consecutive years of increases
- 12
- Last ex-dividend date
- 2026-09-25
- Last payment date
- 2026-10-16
Earnings how computed
- Next earnings report
- 2026-11-17
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-07 ▲ beat (+4.3%)
2026-04 ▲ beat (+0.6%)
2026-01 ▲ beat (+1.5%)
2025-10 ▲ beat (+3.8%)
2025-07 ▲ beat (+2.4%)
2025-04 ▲ beat (+2.5%)
2025-01 ▲ beat (+2.2%)
2024-10 ▲ beat (+0.8%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 19 buy · 9 hold · 0 sell (28 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $105
- Target vs last price
- +18.7%
What our data shows for MDT
- Our model validated 17 trailing price-to-earnings windows for MDT, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $73.75–$105.35.
- The 14-day relative strength index sits at a neutral 59.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for MDT
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent MDT news
TickrTrends' derived news-sentiment signal for MDT is currently leaning positive, computed from recent coverage.
- Medtronic PLC (MDT) Insider Sale: EVP Michael Marinaro Offloads 10,420 Shares (gurufocus.com, 2026-10-17)
TickrTrends take: Michael Marinaro's sale of 10,420 shares represents typical executive portfolio management activity that does not necessarily signal concern about the company's fundamentals or future prospects. TickrTrends currently derives an undervalued verdict for MDT, suggesting the market may not be fully pricing in the company's value relative to its Healthcare sector position and operational performance. Investors focused on valuation should monitor whether insider activity patterns change materially, as sustained selling by multiple insiders could eventually warrant reassessment of the undervalued designation. - Medtronic CEO Martha Geoffrey Sells $4.75M in Shares Amid Solid Dividend Outlook (MDT) (gurufocus.com, 2026-10-16)
TickrTrends take: Medtronic's CEO share sale occurs against the backdrop of TickrTrends' undervalued assessment, suggesting the market may not yet be pricing in the full value of the company's fundamentals and dividend strength. Insider selling activity in the Healthcare sector warrants monitoring by valuation investors, as it can signal confidence levels about future prospects relative to current share prices. The solid dividend outlook mentioned in the headline represents a key factor that valuation-focused analysts typically weigh when assessing whether a stock trades below its intrinsic worth. - EXIT-CVD research consortium launches clinical studies to transform cardiovascular care across Europe (manilatimes.net, 2026-10-15)
TickrTrends take: The EXIT-CVD research consortium's launch of clinical studies represents a development in cardiovascular innovation that could influence MDT's pipeline prospects and competitive positioning in the Healthcare sector. Given TickrTrends' current Undervalued assessment, investors focused on valuation should monitor whether these consortium initiatives create partnership opportunities or competitive pressures that might affect MDT's cardiovascular business segment. The clinical study outcomes and any resulting regulatory or commercial implications could become material factors in reassessing the company's intrinsic value over the medium term.
More MDT news
- Options Traders Show Cautious Pessimism on Medtronic (MDT) Amid Modest Price Dip (gurufocus.com, 2026-10-14)
- Medtronic Completes MiniMed Exchange Offer, Fully Divests MiniMed Group (MDT) (gurufocus.com, 2026-10-14)
- Medtronic (MDT) Exchange Offer for MiniMed Shares Oversubscribed, Shares React (gurufocus.com, 2026-10-12)
- MDT Maintained by BTIG -- Price Target Lowered to $99.00 (gurufocus.com, 2026-10-12)
- Jim Cramer Has Very Different Views on MiniMed (MMED) and Medtronic (MDT) (insidermonkey.com, 2026-10-11)
What people are saying
Follow the MDT conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — MDT's quality grade improved from B to A this week, reflecting an enhancement in the company's fundamental metrics. The stock's sector discount rank also strengthened, moving from number 56 to number 51 among healthcare companies. TickrTrends currently classifies MDT as undervalued based on its derived indicators.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is MDT stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), MDT is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is MDT's TickrTrends verdict?
MDT's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does MDT compare to other Healthcare stocks?
MDT ranks #41 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is MDT overbought or oversold?
MDT's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does MDT pay a dividend?
Yes. MDT paid $2.86 per share over the last twelve months (4 payments), a 3.23% yield on TickrTrends' last price, and has raised the annual total for 12 consecutive years. The last ex-dividend date was 2026-09-25.
When does MDT report earnings next?
MDT's next earnings report is scheduled for 2026-11-17, per the published earnings calendar.
Does MDT usually beat earnings estimates?
Over its last 8 reported quarters MDT beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about MDT?
Of 28 analysts covering MDT, 19 rate it a buy, 9 a hold and 0 a sell - buy-leaning, with a consensus price target of $105 (+18.7% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
MDT vs BAX · MDT vs BDX · MDT vs ENSG · MDT vs INVA · MDT vs JAZZ